Notably, BMS1166 treatment significantly reduced the viability of LV-STING DLBCL cells and, to a less degree, decreased the viability of the STING-KO DLBCL cells (Figure 7C, D). Here, STING1 is linked to diffuse large B-cell lymphoma.